Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richardson Vicks IncfiledCriticalRichardson Vicks Inc
Publication of PT100964ApublicationCriticalpatent/PT100964A/en
Publication of PT100964BpublicationCriticalpatent/PT100964B/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Medicinal Preparation
(AREA)
Abstract
A new topical pharmaceutical compsn. having enhanced penetration through the skin comprises (a) a safe and effective amt. of a pharmaceutical active; and (b) from 0.1-10.0% of a high molecular wt. crosslinked cationic polymer of the formula (A)l(B)m(C)n where the polymer contains a crosslinking agent, where (A) is dialkylaminoalkyl acrylate monomer or its quat. ammonium or acid addn. salt; (B) is a dialkylaminoalkyl methacrylate monomer or its quat. ammonium or acid addn. salt; (C) is acrylamide; l is an integer of 0 or greater; m is an integer of 1 or greater; n is an integer of 0 or greater.
PT10096492A1991-10-161992-10-15
PHARMACEUTICAL COMPOSITIONS FOR TOPIC APPLICATION OF HIGH PENETRATION THROUGH THE SKIN COMPARING CERTAIN SPECIFIC CATIONIC POLYMER
PT100964B
(en)
(S) -adenosyl-L-methionine (SAMe) and its physiologically compatible salts for the treatment of reperfusion injury induced by transient lesion ischemia (Use of (S) -Adenosy-L-Methionine Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia)
Legal Events
Date
Code
Title
Description
FG3A
Patent granted, date of granting
Effective date:
19990419
MM3A
Annulment or lapse
Free format text:
LAPSE DUE TO NON-PAYMENT OF FEES